AAPL327.44-6.30 (-1.89%) ▼|ABBV254.00-0.49 (-0.19%) ▼|ABT101.20+0.52 (+0.51%) ▲|ACN141.65-1.92 (-1.34%) ▼|ADBE228.72-8.53 (-3.60%) ▼|AMAT538.27+8.61 (+1.63%) ▲|AMD511.80+16.04 (+3.23%) ▲|AMGN366.92+0.63 (+0.17%) ▲|AMT168.89-1.17 (-0.69%) ▼|AMZN249.62+2.39 (+0.97%) ▲|AVGO378.57+7.75 (+2.09%) ▲|AXP353.16-2.20 (-0.62%) ▼|BA209.73-4.30 (-2.01%) ▼|BAC60.71-0.56 (-0.91%) ▼|BKNG179.14-2.54 (-1.40%) ▼|BLK1,057.21-14.99 (-1.40%) ▼|BMY61.25+0.51 (+0.84%) ▲|BNY157.78+0.65 (+0.41%) ▲|BRK-B490.83-0.08 (-0.02%) ▼|C129.51+0.15 (+0.12%) ▲|CAT879.13+0.48 (+0.05%) ▲|CL91.73-0.72 (-0.78%) ▼|CMCSA23.64-0.16 (-0.65%) ▼|COF207.61-0.42 (-0.20%) ▼|COP115.18+0.47 (+0.41%) ▲|COST944.73+3.86 (+0.41%) ▲|CRM168.87-1.90 (-1.11%) ▼|CSCO112.52+0.58 (+0.52%) ▲|CVS108.01+0.54 (+0.50%) ▲|CVX188.51+1.13 (+0.60%) ▲|DE591.17-6.07 (-1.02%) ▼|DHR203.49-0.34 (-0.17%) ▼|DIS96.40-1.27 (-1.30%) ▼|DUK126.68+1.67 (+1.34%) ▲|EMR137.09-2.45 (-1.76%) ▼|FDX308.61-4.38 (-1.40%) ▼|GD371.98+3.40 (+0.92%) ▲|GE347.96-0.87 (-0.25%) ▼|GEV1,081.24+23.40 (+2.21%) ▲|GILD133.87-0.41 (-0.31%) ▼|GM76.01-0.06 (-0.08%) ▼|GOOG358.50+12.38 (+3.58%) ▲|GOOGL358.73+11.96 (+3.45%) ▲|GS1,060.00-5.22 (-0.49%) ▼|HD335.22-3.65 (-1.08%) ▼|HON225.17+0.15 (+0.07%) ▲|IBM210.51-2.17 (-1.02%) ▼|INTC97.78+2.74 (+2.88%) ▲|INTU282.98-8.12 (-2.79%) ▼|ISRG346.67+1.25 (+0.36%) ▲|JNJ251.70-1.34 (-0.53%) ▼|JPM341.29+0.19 (+0.06%) ▲|KO82.17+0.61 (+0.75%) ▲|LIN515.25+2.03 (+0.40%) ▲|LLY1,169.32-9.79 (-0.83%) ▼|LMT511.67+2.90 (+0.57%) ▲|LOW204.39-4.35 (-2.08%) ▼|LRCX312.98-0.33 (-0.10%) ▼|MA542.86-0.75 (-0.14%) ▼|MCD268.87+1.16 (+0.43%) ▲|MDLZ60.29-0.71 (-1.16%) ▼|MDT83.32+0.12 (+0.14%) ▲|META643.84-2.17 (-0.34%) ▼|MMM161.29+1.45 (+0.91%) ▲|MO74.58+0.37 (+0.50%) ▲|MRK126.61-0.89 (-0.70%) ▼|MS213.84-1.67 (-0.77%) ▼|MSFT394.25+0.43 (+0.11%) ▲|MU872.51+23.56 (+2.77%) ▲|NEE89.30+0.50 (+0.56%) ▲|NFLX67.54-1.41 (-2.05%) ▼|NKE43.12-0.64 (-1.46%) ▼|NOW99.07-4.17 (-4.04%) ▼|NVDA205.22+2.41 (+1.19%) ▲|ORCL120.58-5.83 (-4.61%) ▼|PEP136.64-0.49 (-0.35%) ▼|PFE24.94-0.12 (-0.46%) ▼|PG149.62-0.36 (-0.24%) ▼|PLTR132.80+0.42 (+0.32%) ▲|PM193.05+0.07 (+0.04%) ▲|QCOM171.76-0.02 (-0.01%) ▼|RTX196.71+3.20 (+1.65%) ▲|SBUX106.09+0.60 (+0.57%) ▲|SCHW100.49-1.07 (-1.05%) ▼|SO95.43+0.13 (+0.14%) ▲|SPG230.04+1.34 (+0.59%) ▲|T21.83+0.02 (+0.09%) ▲|TMO529.02-3.47 (-0.65%) ▼|TMUS193.04+0.61 (+0.32%) ▲|TSLA374.72-6.13 (-1.61%) ▼|TXN289.55+5.53 (+1.95%) ▲|UBER72.23-0.23 (-0.32%) ▼|UNH422.09-4.00 (-0.94%) ▼|UNP300.40-1.35 (-0.45%) ▼|UPS113.72-4.00 (-3.40%) ▼|USB63.27+0.13 (+0.21%) ▲|V359.07+0.51 (+0.14%) ▲|VZ43.48-0.12 (-0.26%) ▼|WFC86.96-0.55 (-0.63%) ▼|WMT113.99-0.25 (-0.22%) ▼|XOM148.37+1.01 (+0.68%) ▲|AAPL327.44-6.30 (-1.89%) ▼|ABBV254.00-0.49 (-0.19%) ▼|ABT101.20+0.52 (+0.51%) ▲|ACN141.65-1.92 (-1.34%) ▼|ADBE228.72-8.53 (-3.60%) ▼|AMAT538.27+8.61 (+1.63%) ▲|AMD511.80+16.04 (+3.23%) ▲|AMGN366.92+0.63 (+0.17%) ▲|AMT168.89-1.17 (-0.69%) ▼|AMZN249.62+2.39 (+0.97%) ▲|AVGO378.57+7.75 (+2.09%) ▲|AXP353.16-2.20 (-0.62%) ▼|BA209.73-4.30 (-2.01%) ▼|BAC60.71-0.56 (-0.91%) ▼|BKNG179.14-2.54 (-1.40%) ▼|BLK1,057.21-14.99 (-1.40%) ▼|BMY61.25+0.51 (+0.84%) ▲|BNY157.78+0.65 (+0.41%) ▲|BRK-B490.83-0.08 (-0.02%) ▼|C129.51+0.15 (+0.12%) ▲|CAT879.13+0.48 (+0.05%) ▲|CL91.73-0.72 (-0.78%) ▼|CMCSA23.64-0.16 (-0.65%) ▼|COF207.61-0.42 (-0.20%) ▼|COP115.18+0.47 (+0.41%) ▲|COST944.73+3.86 (+0.41%) ▲|CRM168.87-1.90 (-1.11%) ▼|CSCO112.52+0.58 (+0.52%) ▲|CVS108.01+0.54 (+0.50%) ▲|CVX188.51+1.13 (+0.60%) ▲|DE591.17-6.07 (-1.02%) ▼|DHR203.49-0.34 (-0.17%) ▼|DIS96.40-1.27 (-1.30%) ▼|DUK126.68+1.67 (+1.34%) ▲|EMR137.09-2.45 (-1.76%) ▼|FDX308.61-4.38 (-1.40%) ▼|GD371.98+3.40 (+0.92%) ▲|GE347.96-0.87 (-0.25%) ▼|GEV1,081.24+23.40 (+2.21%) ▲|GILD133.87-0.41 (-0.31%) ▼|GM76.01-0.06 (-0.08%) ▼|GOOG358.50+12.38 (+3.58%) ▲|GOOGL358.73+11.96 (+3.45%) ▲|GS1,060.00-5.22 (-0.49%) ▼|HD335.22-3.65 (-1.08%) ▼|HON225.17+0.15 (+0.07%) ▲|IBM210.51-2.17 (-1.02%) ▼|INTC97.78+2.74 (+2.88%) ▲|INTU282.98-8.12 (-2.79%) ▼|ISRG346.67+1.25 (+0.36%) ▲|JNJ251.70-1.34 (-0.53%) ▼|JPM341.29+0.19 (+0.06%) ▲|KO82.17+0.61 (+0.75%) ▲|LIN515.25+2.03 (+0.40%) ▲|LLY1,169.32-9.79 (-0.83%) ▼|LMT511.67+2.90 (+0.57%) ▲|LOW204.39-4.35 (-2.08%) ▼|LRCX312.98-0.33 (-0.10%) ▼|MA542.86-0.75 (-0.14%) ▼|MCD268.87+1.16 (+0.43%) ▲|MDLZ60.29-0.71 (-1.16%) ▼|MDT83.32+0.12 (+0.14%) ▲|META643.84-2.17 (-0.34%) ▼|MMM161.29+1.45 (+0.91%) ▲|MO74.58+0.37 (+0.50%) ▲|MRK126.61-0.89 (-0.70%) ▼|MS213.84-1.67 (-0.77%) ▼|MSFT394.25+0.43 (+0.11%) ▲|MU872.51+23.56 (+2.77%) ▲|NEE89.30+0.50 (+0.56%) ▲|NFLX67.54-1.41 (-2.05%) ▼|NKE43.12-0.64 (-1.46%) ▼|NOW99.07-4.17 (-4.04%) ▼|NVDA205.22+2.41 (+1.19%) ▲|ORCL120.58-5.83 (-4.61%) ▼|PEP136.64-0.49 (-0.35%) ▼|PFE24.94-0.12 (-0.46%) ▼|PG149.62-0.36 (-0.24%) ▼|PLTR132.80+0.42 (+0.32%) ▲|PM193.05+0.07 (+0.04%) ▲|QCOM171.76-0.02 (-0.01%) ▼|RTX196.71+3.20 (+1.65%) ▲|SBUX106.09+0.60 (+0.57%) ▲|SCHW100.49-1.07 (-1.05%) ▼|SO95.43+0.13 (+0.14%) ▲|SPG230.04+1.34 (+0.59%) ▲|T21.83+0.02 (+0.09%) ▲|TMO529.02-3.47 (-0.65%) ▼|TMUS193.04+0.61 (+0.32%) ▲|TSLA374.72-6.13 (-1.61%) ▼|TXN289.55+5.53 (+1.95%) ▲|UBER72.23-0.23 (-0.32%) ▼|UNH422.09-4.00 (-0.94%) ▼|UNP300.40-1.35 (-0.45%) ▼|UPS113.72-4.00 (-3.40%) ▼|USB63.27+0.13 (+0.21%) ▲|V359.07+0.51 (+0.14%) ▲|VZ43.48-0.12 (-0.26%) ▼|WFC86.96-0.55 (-0.63%) ▼|WMT113.99-0.25 (-0.22%) ▼|XOM148.37+1.01 (+0.68%) ▲|
24.9 C
New York
Monday, July 20, 2026

Tag: organ

newssourceFORcompanyinformationcontent1releasesmarket

Chiesi Group and Arbor Biotechnologies Announce ABO-101 Granted Orphan Drug Designation by European Commission for Primary Hyperoxaluria

 ABO-101 is an investigational gene editing therapy designed to address the underlying disease biology of PH1 by reducing hepatic oxalate production

Vascarta Announces Phase I Results of VAS-101 Administered Sublingually in Sickle Cell Disease Patients

SUMMIT, N.J., June 24, 2026 /PRNewswire/ -- Vascarta Inc., a clinical-stage biopharmaceutical company advancing innovative treatments for pain and inflammation, announced today the successful...

Lungpacer Medical Announces Presentation of DONATE Data Reporting an Increase in Availability of Donor Lungs

Data shows transvenous phrenic nerve stimulation reduces lung collapse and significantly increases availability of lungs that meet transplant criteria

13 Press Releases You Need to See This Week

Including FOX's plans to acquire Roku, a ranking of the best universities around the world and the return of Fried Apple Pie at McDonald's.NEW...

$GRAL Fraud Notice: GRAIL, Inc. Accused of Securities Fraud over Trial Results in Filed Class Action Lawsuit – Investors Notified to Contact BFA Law

GRAIL, Inc. Accused of Securities Fraud over Trial Results in Filed Class Action Lawsuit – Investors Notified to Contact BFA Law

Rogers Brings Blue Jays Spirit to Calgary with New Ballpark Experience at Rogers Charity Classic

Hole 16 activation celebrates the Toronto Blue Jays’ 50th season, raises funds for Jays Care Foundation 
Hole 16 activation celebrates the Toronto Blue Jays’ 50th season, raises funds for Jays Care Foundation

Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology...

HAMPTON, N.J., June 14, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today the presentation of long-term results from the Phase 2 study of barzolvolimab in a flash talk session at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Meeting in Istanbul, Türkiye. The data presented demonstrated that barzolvolimab treatment results in rapid, significant, and durable improvements in angioedema in patients with chronic spontaneous urticaria (CSU) refractory to antihistamines. These results were sustained off-treatment, seven months after completion of barzolvolimab dosing (Week 76). The data continue to demonstrate barzolvolimab’s potential to shift the goal of CSU treatment from symptom control to disease modification and further support the ongoing Phase 3 trials of barzolvolimab in CSU.

Phase 3 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with Hypoparathyroidism

COPENHAGEN, Denmark, June 13, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced Week 182 data from its completed Phase 3 PaTHway Trial showing that long-term treatment with TransCon PTH (palopegteriparatide) demonstrated sustained efficacy and safety in adults with hypoparathyroidism. Over the three-and-a-half-year duration of the trial, TransCon PTH replicated the systemic actions of endogenous PTH, with a balanced, beneficial impact on the main target organ systems – CNS, kidney, small intestine, and bone – as demonstrated by improved quality of life and normalized and stable urine calcium, serum calcium, serum phosphate, and bone mineral density. These benefits were sustained while enabling independence from conventional therapy with active vitamin D and calcium.

XORTX Announces Election to Voluntary Delist from the TSX Venture Exchange

CALGARY, Alberta, June 12, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, announces that the Company has elected to voluntarily delist its common shares from the TSX Venture Exchange (“TSXV”). The Company will provide additional information on timing for the completion of the delisting of its common shares in a separate press release.

In Vitro Toxicology Testing Market worth $20.97 billion by 2031 | MarketsandMarkets™

DELRAY BEACH, Fla., June 12, 2026 /PRNewswire/ -- According to MarketsandMarkets™, the In Vitro Toxicology Testing Market is projected to grow from about USD...

In Vitro Toxicology Testing Market worth $20.97 billion by 2031 | MarketsandMarkets™

DELRAY BEACH, Fla., June 12, 2026 /PRNewswire/ -- According to MarketsandMarkets™, the In Vitro Toxicology Testing Market is projected to grow from about USD...

KFSH Highlights the Strategic Value of Tertiary Care AI Datasets in Advancing Precision Medicine and Clinical Innovation

RIYADH, Saudi Arabia, June 12, 2026 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital & Research Centre (KFSH) will use its participation at HLTH Europe 2026, taking place from June 15 to 18 in Amsterdam, to highlight the strategic value of tertiary care datasets as a foundation for advancing artificial intelligence, precision medicine, and clinical innovation in highly specialized healthcare.

Eliaz Therapeutics Launches Reg CF Raise to Advance First Device Targeting Sepsis

Eliaz Therapeutics Launches Reg CF Raise to Advance First Device Targeting Sepsis

Humacyte, Inc. Announces Pricing of Public Offering of Common Stock

DURHAM, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the pricing of an underwritten public offering of 47,619,048 shares of its common stock at a public offering price of $1.05 per share. The aggregate gross proceeds from this offering are expected to be $50 million, before deducting underwriting discounts and commissions and other offering expenses payable by Humacyte. The closing of the offering is expected to occur on or about June 12, 2026, subject to the satisfaction of customary closing conditions. In addition, Humacyte has granted the underwriters an option for a period of 30 days to purchase up to an additional 7,142,857 shares of Humacyte’s common stock at the public offering price, less underwriting discounts and commissions. All of the shares of common stock are being sold by Humacyte.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsOrgan

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers